Insider · CIK 0001959318
Natalie Ee Mun Leong
Files at QNRX (Quoin Pharmaceuticals, Ltd.). First filing -, latest -.
Natalie Ee Mun Leong files SEC Form 4 as director at QNRX (Quoin Pharmaceuticals, Ltd.). No open-market trade is on file; the transactions below are grants, exercises and other rows that carry no view on the price.
A track record needs three past buys with six months of prices behind them; Natalie Ee Mun Leong has 0, so none is measured yet.
Signals
This insider’s open-market buys and sells, scored.
Transactions
Every row this insider has filed, 4 in all, newest first.
| Date | Company | Transaction | Shares | Price | Value | Holdings after | Filed |
|---|---|---|---|---|---|---|---|
| Feb 4, 2026 | QNRX Quoin Pharmaceuticals, Ltd. | AGrant or award Share Option (Right to Buy)derivative | +12,211 | $0.00 | $0 | 12,211 | Feb 6, 2026 |
| Aug 21, 2025 | QNRX Quoin Pharmaceuticals, Ltd. | AGrant or award Share Option (Right to Buy)derivative | +4,105 | $0.00 | $0 | 4,105 | Aug 25, 2025 |
| May 29, 2025 | QNRX Quoin Pharmaceuticals, Ltd. | AGrant or award Share Option (Right to Buy)derivative | +7,760 | $0.00 | $0 | 7,760 | Jun 2, 2025 |
| Dec 9, 2024 | QNRX Quoin Pharmaceuticals, Ltd. | AGrant or award Share Option (Right to Buy)derivative | +50,714 | $0.00 | $0 | 50,714 | Dec 10, 2024 |
Questions about Natalie Ee Mun Leong
Answered from the filings on this page, as of the latest one.
Is Natalie Ee Mun Leong buying or selling?
Natalie Ee Mun Leong has no open-market buy or sell on SEC Form 4; the filings on record are grants, exercises and other transactions.
How did Natalie Ee Mun Leong's past buys perform?
Not measured yet. InsiderTell needs three past buys with six months of prices to publish a track record, and Natalie Ee Mun Leong has 0.
Where does Natalie Ee Mun Leong file Form 4?
Natalie Ee Mun Leong has filed Form 4 at QNRX (Quoin Pharmaceuticals, Ltd.). A Form 4 is required of officers, directors and holders of more than 10% of a share class within two business days of a trade.
Not investment advice. Scores and forward returns are decision support built from public SEC filings and past prices; they describe what happened after comparable filings, not what will happen after this one. Do your own research and size your risk.